Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series.

Details

Serval ID
serval:BIB_75D58C83DF0E
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series.
Journal
Hematological Oncology
Author(s)
Provencher S., Ferlay C., Alaoui-Slimani K., Devidas A., Lepretre S., de Prijck B., Sebban C., de la Fouchardiere A., Chassagne-Clement C., Ketterer N., Thyss A., Delannoy A., Tilly H., Biron P., Blay J.Y., Ghesquières H.
ISSN
1099-1069 (Electronic)
ISSN-L
0278-0232
Publication state
Published
Issued date
2011
Volume
29
Number
1
Pages
10-16
Language
english
Abstract
There is very limited data on isolated systemic relapses of primary central nervous system lymphomas (PCNSL). We retrospectively reviewed the clinical characteristics and outcome of 10 patients with isolated systemic disease among 209 patients with PCNSL mainly treated with methotrexate-based chemotherapy (CT) with or without radiation therapy (RT). Isolated systemic relapse remained rare (4.8%, 10/209 patients). Median time from initial diagnosis to relapse was 33 months (range, 3-94). Sites of relapse were mostly extranodal. Three patients presented with early extra-cerebral (EC) relapse 3, 5 and 8 months from the beginning of initial treatment, respectively, and 7 patients had later relapses (range, 17-94 months). Treatment at relapse included surgery alone, RT alone, CT with or without radiotherapy, or CT with autologous stem cell transplantation (ASCT). Median overall survival (OS) after relapse was 15.5 months (range, 5.8-24.5) compared to 4.6 months (range, 3.6-6.5) for patients with central nervous system (CNS) relapse (p = 0.35). In conclusion, isolated systemic relapses exist but are infrequent. Early EC relapse suggests the presence of systemic disease undetectable by conventional evaluation at initial diagnosis. Patient follow-up must be prolonged because systemic relapse can occur as late as 10 years after initial diagnosis. Whether EC relapses of PCNSL have a better prognosis than CNS relapses needs to be assessed in a larger cohort. Copyright © 2010 John Wiley & Sons, Ltd.
Keywords
aggressive non hodgkin's lymphoma, primary CNS lymphoma, systemic relapse, primary cns lymphoma, high-dose methotrexate, b-cell lymphoma, term-follow-up, detude-des-lymphomes, phase-ii, deferred radiotherapy, european organization, chemotherapy, brain
Pubmed
Web of science
Create date
31/03/2011 14:46
Last modification date
20/08/2019 14:33
Usage data